The DOI matches its Crossref record; 67 of the 74 references it cites were found in a registry or an index; 42 of the 96 sources its claims cite were checked for support.
2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism
Open accessAbstract
Objectives: Central hypothyroidism (CeH) is a rare form of hypothyroidism characterized by insufficient thyroid stimulation due to disturbed pituitary and/or hypothalamic functioning. Due to its origin and the whole clinical context, CeH represents a challenging condition in clinical practice as it is characterized by suboptimal accuracy of clinical and biochemical parameters for diagnosis and management. Since no expert consensus or guidance for this condition is currently available, a task force of experts received the commitment from the European Thyroid Association (ETA) to prepare this document based on the principles of clinical evidence. Study Design: The task force started to work in February 2017 and after a careful selection of appropriate references (cohort studies, case reports, expert opinions), a preliminary presentation and live discussion during the 2017 ETA meeting, and several revision rounds, has prepared a list of recommendations to support the diagnosis and management of patients with CeH. Results: Due to the particular challenges of this rare condition in the different ages, the target users of this guidance are pediatric and adult endocrinologists. Experts agreed on the need to recognize and treat overt CeH at all ages, whereas treatment of milder forms may be dispensable in the elderly (> 75 years). Conclusions: Despite the lack of randomized controlled clinical trials, the experts provide 34 recommendations supported by variable levels of strength that should improve the quality of life of the affected patients and reduce the metabolic and hormonal consequences of inadequate management.
Overview
CoChat Summary
TL;DR
These 2018 European Thyroid Association guidelines provide expert guidance on diagnosing and managing central hypothyroidism (CeH), a rare condition caused by insufficient pituitary/hypothalamic stimulation of the thyroid. The task force issued 34 GRADE-rated recommendations, agreeing that overt CeH should be recognized and treated at all ages, while treatment of milder forms may be dispensable in patients older than 75 years.
Key findings
- CeH prevalence was estimated to range from 1:16,000 to about 1:100,000 in general adult or neonatal populations, with no evidence of sex predominance.
- Diagnosis should be considered with low free thyroxine (FT4) and low or normal TSH, confirmed on at least two separate determinations after excluding conditions in Table 3; genetic analyses are recommended in congenital, familial, childhood-onset, or otherwise unexplained CeH.
- L-T4 monotherapy is the standard treatment; severe congenital CeH should start as soon as possible, optimally within 2 weeks after birth, at 10–12 μg/kg body weight/day, while milder congenital forms may start at 5–10 μg/kg bw/day.
- Adult replacement targets are 1.2–1.6 μg/kg bw/day in patients younger than 60 years and 1.0–1.2 μg/kg bw/day in adults older than 60 years or younger patients with cardiac disease; treatment of milder CeH may be dispensable in elderly patients >75 years.
Methods
- An ETA task force was formed at the end of 2016 and worked from February 2017, performing a systematic PubMed search using “central hypothyroidism,” “secondary hypothyroidism,” and “tertiary hypothyroidism” up to February 2018, supplemented by personal files, references, and textbooks.
- The task force assessed cohort studies, case reports, and expert opinions; only 1 randomized controlled trial was available, and very few reports fulfilled established criteria, so the document is described as an “expert guidance.”
- Recommendations were rated using GRADE as strong (1) or weak (2), with evidence quality graded from ∅○○○ (very low) to ∅∅∅∅ (high); the draft was posted to the ETA members-only section for 4 weeks and verified with AGREE II.
Limitations
- Paper-stated: there is a lack of randomized controlled clinical trials, with only 1 RCT available and very few reports meeting criteria; the guidance is therefore based on variable levels of evidence, including retrospective studies and expert opinions.
- Paper-stated: diagnosis of milder defects, characterized by FT4 still within the normal range (mild or hidden CeH), remains problematic, and the relative application of supportive tests may vary by setting and local regulations.
- Evident from the text: many recommendations rely on low or very low quality evidence, and some evidence levels were upgraded based on studies conducted in primary hypothyroidism rather than CeH itself.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
31 Valid · 0 Not valid · 14 Not checked · 12 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In children, L-T4 treatment was reported to promote an acceleration of growth velocity allowing attainment of target height [11, 28, 43].”
What the sources say
- Partly supportedcites [11] Bonomi M, Busnelli M, Beck-Peccoz P, Costanzo D, Antonica F, Dolci C, Pilotta A, Buzi F, Persani L: A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 2009; 360: 731–734. sourceExperimental — accuracy not yet measured
Table 1 (page not provided) reports that the proband received levothyroxine and reached 178 cm as an adult, within his parental target-height range of 172 ± 10 cm. The paper does not report an acceleration in growth velocity or establish this treatment effect in children generally. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [28] Collu R, Tang J, Castagne J, Lagace G, Masson N, Huot C, Deal C, Delvin E, Faccenda E, Eidne KA, Van Vliet G: A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82: 1561–1565. source
- Not checked — no full text of the sourcecites [43] Rose SR: Cranial irradiation and central hypothyroidism. Trends Endocrinol Metab 2001; 12: 97–104. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“If untreated within a few weeks of postnatal life, these patients develop cretinism comparable to patients with severe primary congenital hypothyroidism [26, 27].”
What the sources say
- Not checked — no full text of the sourcecites [26] Bonomi M, Proverbio MC, Weber G, Chiumello G, Beck-Peccoz P, Persani L: Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene. J Clin Endocrinol Metab 2001; 86: 1600–1604. source
- Partly supportedcites [27] Miyai K: Congenital thyrotropin deficiency – from discovery to molecular biology, postgenome and preventive medicine. Endocr J 2007; 54: 191–203. sourceExperimental — accuracy not yet measured
Section 1.2 (page unavailable) reports that severe cases of congenital isolated TSH deficiency showed signs of nongoitrous cretinism; section 1.3 identifies homozygous or compound-heterozygous TSHβ mutations in this condition. Section 4 says early treatment can prevent irreversible effects of congenital hypothyroidism, but the copy does not specify a window of a few postnatal weeks or compare these patients’ outcomes directly with severe primary congenital hypothyroidism. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Though prolonged neonatal jaundice was reported in 1 female, even complete TRH resistance does not cause severe neonatal hypothyroidism.”
What the sources say
- Supportedcites [11] Bonomi M, Busnelli M, Beck-Peccoz P, Costanzo D, Antonica F, Dolci C, Pilotta A, Buzi F, Persani L: A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 2009; 360: 731–734. source
In “A Family with Complete Resistance to Thyrotropin-Releasing Hormone” (page not available in our copy), the authors report that thyroid stimulation was not overtly impaired at birth or during infancy despite complete resistance to TRH. They contrast the family’s outcomes with severe hypothyroidism seen in patients with thyrotropin-beta mutations, supporting the cited point about severe neonatal hypothyroidism. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [28] Collu R, Tang J, Castagne J, Lagace G, Masson N, Huot C, Deal C, Delvin E, Faccenda E, Eidne KA, Van Vliet G: A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82: 1561–1565. source
- Supportedcites [29] Koulouri O, Nicholas AK, Schoenmakers E, Mokrosinski J, Lane F, Cole T, Kirk J, Farooqi IS, Chatterjee VK, Gurnell M, Schoenmakers N: A novel thyrotropin-releasing hormone receptor missense mutation (P81R) in central congenital hypothyroidism. J Clin Endocrinol Metab 2016; 101: 847–851. source
The Results (TRHR signaling and Ligand binding; page not provided) report that the P81R receptor was nonfunctional in both signaling assays and had absent ligand binding. The Results (Clinical and biochemical features) document neonatal hypothyroidism in the affected infant, while the Discussion describes her biochemical defect as moderate rather than profound and notes similarly mild findings in earlier TRHR cases. (LLM, conf=0.87)
- Partly supportedcites [30] Garcia M, Gonzalez de Buitrago J, Jimenez-Roses M, Pardo L, Hinkle PM, Moreno JC: Central hypothyroidism due to a TRHR mutation causing impaired ligand affinity and transactivation of Gq. J Clin Endocrinol Metab 2017; 102: 2433–2442. sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) reports moderate hypothyroidism in three patients with severely impaired TRHR signaling, all missed by TSH-based neonatal screening. The Discussion (page unavailable) says previously described mutations had no residual activity. These observations are consistent with the main point, but the paper does not establish that complete resistance never causes severe neonatal hypothyroidism, and the cited passages do not report prolonged neonatal jaundice in a female patient. (LLM, conf=0.83)
plainn = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The diagnosis in 3 of 4 probands with biallelic TRHR mutations was made during childhood because of delayed growth accompanied by lethargy and fatigue or by overweight.”
What the sources say
- Partly supportedcites [11] Bonomi M, Busnelli M, Beck-Peccoz P, Costanzo D, Antonica F, Dolci C, Pilotta A, Buzi F, Persani L: A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 2009; 360: 731–734. sourceExperimental — accuracy not yet measured
In the section “A Family with Complete Resistance to Thyrotropin-Releasing Hormone” (page unavailable), Table 1 places this paper’s proband at age 11 with height in the 3rd–10th percentile, and the text mentions a previously reported 9-year-old with a similar presentation. Our copy does not report a group of four probands or establish that three were diagnosed because of delayed growth accompanied by lethargy, fatigue, or overweight. (LLM, conf=0.80)
- Not checked — no full text of the sourcecites [28] Collu R, Tang J, Castagne J, Lagace G, Masson N, Huot C, Deal C, Delvin E, Faccenda E, Eidne KA, Van Vliet G: A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82: 1561–1565. source
- Partly supportedcites [29] Koulouri O, Nicholas AK, Schoenmakers E, Mokrosinski J, Lane F, Cole T, Kirk J, Farooqi IS, Chatterjee VK, Gurnell M, Schoenmakers N: A novel thyrotropin-releasing hormone receptor missense mutation (P81R) in central congenital hypothyroidism. J Clin Endocrinol Metab 2016; 101: 847–851. sourceExperimental — accuracy not yet measured
The Discussion reports growth retardation in two previously described children with biallelic TRHR mutations. The Results (Clinical and biochemical features; page unavailable) say this paper’s patient was diagnosed after presenting with neonatal jaundice and had grown normally; the paper does not establish that three of four were diagnosed because of delayed growth accompanied by lethargy, fatigue, or overweight. (LLM, conf=0.87)
- Partly supportedcites [30] Garcia M, Gonzalez de Buitrago J, Jimenez-Roses M, Pardo L, Hinkle PM, Moreno JC: Central hypothyroidism due to a TRHR mutation causing impaired ligand affinity and transactivation of Gq. J Clin Endocrinol Metab 2017; 102: 2433–2442. sourceExperimental — accuracy not yet measured
The Abstract describes two patients referred at ages 9 and 11 with short stature and symptoms including lethargy and fatigue; a third was diagnosed at two months. The Discussion says the paper’s 8-year-old patient was overweight, but came to medical attention because of abnormal thyroid tests at a routine checkup, not because of overweight. (LLM, conf=0.88)
plainstates a causen = 4- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several other drugs (e.g., glucocorticoids, anti-epileptics, somatostatin) have transient or controversial TSH-suppressive effects [1, 38] (see Table 3).”
What the sources say
- Not checked — no full text of the sourcecites [1] Persani L: Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 2012; 97: 3068–3078. source
- Partly supportedcites [38] Haugen BR: Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2009; 23: 793–800. sourceExperimental — accuracy not yet measured
The Somatostatin analogs section describes TSH suppression as primarily transient, and Other medications that may affect TSH levels says whether antiepileptics affect TSH remains controversial. The Glucocorticoids section confirms TSH suppression but does not characterize that effect as transient or controversial; it says long-term use does not appear to cause clinically evident central hypothyroidism. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
33 more claims · 15 with their cited sources checked
Create a free account to see all 57 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“L-thyroxine (L-T4) monotherapy is the standard treatment for PH (4–6) and CH (4, 5, 7), and SCH patients candidate for replacement (4, 5, 8).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reported incidence of central CH detected through neonatal screening lies between 1 in 30,000 and 1 in 16,000, depending on the screening strategy (22–26).”
From Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update—An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The incidence of CH partly depends on the screening strategy; based on data from a number of screening programs, the incidence of primary CH lies between 1 in 3000 and 1 in 2000; the highest reported incidence of central CH is ∼1 in 16,000 (1/+++).”
From Congenital Hypothyroidism: A 2020–2021 Consensus Guidelines Update—An ENDO-European Reference Network Initiative Endorsed by the European Society for Pediatric Endocrinology and the European Society for Endocrinology (2021) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, unfortunately, biologically inactive TSH is mostly measurable by the TSH immunoassays, and therefore serum TSH is useless in the diagnosis of central hypothyroidism and in the monitoring of replacement (91).”
From ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism (2025) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Central CH is more frequently part of MPHD and can be associated with one or more other pituitary hormone deficiences.”
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Path · p. 3
“7 additional members were selected”
§ The Path · p. 3
“(G.B., U.F.-D., E.F., D.M., N.S., P.T.)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ How Should CeH Patients Be Managed and Treated? · p. 8
“thyroid replacement must be started after steroid therapy in order to prevent the possible precipitation of an adrenal crisis, and the assessment of corticotrope function can be postponed (Recommendation 19).”
§ Recommendation 20 * ^ · p. 11
“## Recommendation 20 * ^ In CeH patients, we recommend starting replacement treatment with L-T4 only after evidence of conserved cortisol secretion.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ How Should CeH Patients Be Managed and Treated? · p. 9
“when the concomitant treatments listed in Recommendation 31 are withdrawn (Recommendation 33).”
§ Recommendation 32 * ^ · p. 11
“## Recommendation 32 * ^ In CeH patients, we recommend to consider up-titration of the L-T4 dose in all conditions listed below: - --retarded psychomotor and cognitive development in infants and children; - --introduction of GH replacement therapy; - --introduction of estrogen replacement therapy or oral contraceptives;”
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease
(2003) · Thyroid · doi:10.1089/105072503321086962 · Cited by 1,212
Self-citationLéger, J., Olivieri, A., Donaldson, M., Torresani, T., Krude, H., van Vliet, G., Polak, M., Butler, G., & on behalf of ESPE-PES-SLEP-JSPE-APEG-APPES-ISPAE, A. T. C. H. C. C. G. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1891 · Cited by 569
Demers, L. M., & Spencer, C. A. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01681.x · Cited by 460
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Swiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302
Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges
Persani, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1616 · Cited by 295
Self-citationIncreased need for thyroxine in women with hypothyroidism during estrogen therapy
Arafah, B. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442302 · Cited by 267
Cited by
van Trotsenburg, P., Stoupa, A., Léger, J., Rohrer, T., Peters, C., Fugazzola, L., Cassio, A., Heinrichs, C., Beauloye, V., Pohlenz, J., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0333 · Cited by 469
“Other causes of this fT4–TSH combination are nonthyroidal illness, premature birth (with a correlation between severity and GA/birthweight), and certain forms of reduced sensitivity to TH (25).”
BackgroundInfluentialSelf-citationChaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Impact of COVID-19 on the thyroid gland: an update
Scappaticcio, L., Pitoia, F., Esposito, K., Piccardo, A., & Trimboli, P. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09615-z · Cited by 259
Husebye, E. S., Castinetti, F., Criseno, S., Curigliano, G., Decallonne, B., Fleseriu, M., Higham, C. E., Lupi, I., Paschou, S. A., Toth, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0689 · Cited by 192
European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
Pasquali, R., Casanueva, F., Haluzik, M., van Hulsteijn, L., Ledoux, S., Monteiro, M. P., Salvador, J., Santini, F., Toplak, H., & Dekkers, O. M. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0893 · Cited by 188
Metadata
- Authors
- Persani, L., Brabant, G., Dattani, M., Bonomi, M., Feldt-Rasmussen, U., Fliers, E., Gruters, A., Maiter, D., Schoenmakers, N., & van Trotsenburg, A. S. P.
- Affiliations
- University of Milan (IT)
- University of Lübeck (DE)
- University College London (GB)
- 5Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
- Amsterdam UMC Location University of Amsterdam (NL)
- 7Department for Pediatric Endocrinology and Diabetes, Charité University Medicine, Berlin, Germany
- Cliniques Universitaires Saint-Luc (BE)
- University of Cambridge (GB)
- 11Department of Pediatric Endocrinology, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- Corresponding author
- Persani, Luca
- ORCID
- Venue
- European Thyroid Journal
- Publisher
- Bioscientifica
- Published
- 2018-07-19
- Volume
- 7
- Issue
- 5
- Pages
- 225-237
- ISSN
- 2235-0640 (ISSN-L)
- 2235-0802
- PMC
- PMC6198777
- OpenAlex
- W2883658667
- Cited by
- 222
- References
- 74
- Citations by year
- 2026: 29 · 2025: 24 · 2024: 23 · 2023: 24 · 2022: 39 · 2021: 38 · 2020: 22 · 2019: 18 · 2018: 3
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Thyroid Journal (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust (100574/Z/12/Z, 100585/Z/12/Z)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- central hypothyroidism, pituitary dysfunction, hypothalamic dysfunction, thyroid-stimulating hormone deficiency, diagnosis, treatment, pediatric hypothyroidism, elderly patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. https://app.cochat.ai/papers/10.1159/000491388
- The paper
- Persani, L., Brabant, G., Dattani, M., Bonomi, M., Feldt-Rasmussen, U., Fliers, E., Gruters, A., Maiter, D., Schoenmakers, N., & van Trotsenburg, A. S. P. (2018). 2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism. European Thyroid Journal. https://doi.org/10.1159/000491388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.